期刊
VACCINE
卷 26, 期 52, 页码 6894-6900出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.09.082
关键词
Ebola virus; Marburg virus; Filovirus; Nonhuman primates; Aerosol; Vaccines
资金
- Defense Threat Reduction Agency [04-4-7J-012]
- Public Health Agency of Canada
- Canadian Institutes of Health Research [MOP-39321]
- Chemical, Biological, Radiological, and Nuclear (CBRN) Research and Technology Initiative (CRTI)
Considerable progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against Ebola and Marburg viruses. A vaccine based oil recombinant vesicular stomatitis virus (VSV) seems to be particularly robust as it can also confer protection when administered as a postexposure treatment. While filoviruses are not thought to be transmitted by aerosol in nature the inhalation route is among the most likely portals of entry ill the setting of a bioterrorist event. At present, all candidate filoviral vaccines have been evaluated against parenteral challenges but none have been tested against an aerosol exposure. Here, we evaluated our recombinant VSV-based Zaire ebolavirus (ZEBOV) and Marburg Virus (MARV) vaccines against aerosol challenge ill cynomolgus macaques. All monkeys vaccinated with a VSV vector expressing the glycoprotein of ZEBOV were completely protected against an aerosol exposure of ZEBOV. Likewise, all monkeys vaccinated with a VSV vector expressing the glycoprotein of MARV were completely protected against all aerosol exposure of MARV. All control animals challenged by the aerosol route with either ZEBOV or MARV succumbed. Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据